Early observations and pilot data that first suggested a new direction
RAAS blockade with ACE inhibitors and ARBs was the only proven nephroprotective strategy for decades. The CREDENCE trial in 2019 provided the first evidence that an SGLT2 inhibitor could reduce kidney outcomes in patients with diabetic kidney disease. Among 4,401 patients with T2D and CKD, canagliflozin reduced the composite kidney endpoint by 30% (HR 0.70; 95% CI 0.59-0.82; p=0.00001). The trial was stopped early for efficacy, transforming SGLT2 inhibitors from glucose-lowering agents to kidney-protective therapies.
Landmark RCTs and pivotal trials that established the evidence base
The DAPA-CKD trial extended SGLT2 inhibitor nephroprotection beyond diabetic kidney disease. Among 4,304 patients with CKD (including 32% without diabetes), dapagliflozin reduced the primary composite endpoint by 39% (HR 0.61; 95% CI 0.51-0.72; p<0.001). The benefit was consistent regardless of diabetes status—a transformative finding establishing SGLT2 inhibitors as universal CKD therapies. The trial was also stopped early for overwhelming efficacy.
Follow-up studies, subgroup analyses, and real-world validation
EMPA-KIDNEY confirmed the SGLT2 inhibitor benefit across the broadest CKD population studied, including patients with eGFR as low as 20 mL/min and those with minimal proteinuria. Among 6,609 patients, empagliflozin reduced the primary endpoint by 28% (HR 0.72; 95% CI 0.64-0.82; p<0.001). The FIDELIO-DKD trial demonstrated that finerenone, a nonsteroidal MRA, provided additional nephroprotection on top of maximized RAAS blockade, reducing kidney events by 18% (HR 0.82; 95% CI 0.73-0.93; p=0.001) in 5,734 patients with diabetic kidney disease.
Integration into clinical practice guidelines and recommendations
KDIGO 2024 guidelines established a four-pillar approach to CKD management: RAAS inhibition, SGLT2 inhibitors, nonsteroidal MRAs (for diabetic CKD with residual albuminuria), and GLP-1 RAs (for T2D with CKD). SGLT2 inhibitors are recommended for virtually all patients with CKD regardless of diabetes status, representing the most significant expansion of nephroprotective therapy in three decades.
KDIGO
Four-pillar CKD management: RAAS blockade + SGLT2 inhibitor for all CKD; add finerenone for DKD with residual albuminuria; add GLP-1 RA for T2D with CKD
ADA
SGLT2 inhibitor recommended for all patients with T2D and eGFR ≥20 mL/min; finerenone for DKD with albuminuria on maximal RAAS blockade
Now
Current standard of care and ongoing research directions
CKD management has been transformed by an unprecedented expansion of evidence-based therapies. The combination of RAAS blockade, SGLT2 inhibitors, nonsteroidal MRAs, and GLP-1 RAs offers complementary nephroprotection through distinct mechanisms. Implementation challenges include ensuring access, managing polypharmacy, and identifying patients who will benefit most from each agent. Ongoing research explores combination strategies and novel targets including endothelin receptor antagonists and anti-inflammatory agents.
Do SGLT2 inhibitors work for CKD in patients without diabetes?+
The DAPA-CKD trial showed dapagliflozin reduced kidney progression by 39% (HR 0.61) in patients with CKD regardless of diabetes status—32% of participants did not have diabetes. EMPA-KIDNEY (6,609 patients) confirmed this across an even broader CKD population. SGLT2 inhibitors are now recommended for all patients with CKD with eGFR ≥20 mL/min.
What is finerenone and how does it differ from spironolactone?+
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) with greater receptor selectivity than spironolactone. In the FIDELIO-DKD trial (5,734 patients), it reduced kidney events by 18% (HR 0.82) and cardiovascular events by 14% (HR 0.86) on top of maximized RAAS blockade. Unlike spironolactone, it has minimal anti-androgenic side effects and lower hyperkalemia rates.
